Abstract Search

ISEF | Projects Database | Finalist Abstract

Back to Search Results | Print PDF

Anti-Skin Cancer Lotion

Booth Id:
BMED069

Category:
Biomedical and Health Sciences

Year:
2017

Finalist Names:
Qadir, Sadia (School: Manhasset High School)

Abstract:
The human epidermis undergoes continuous homeostatic regeneration and mutations, these mutations disturb the balance of homeostatic regeneration of epidermis which leads to Skin Cancer. Tumours that arise in skin are primarily of three types. Basal cell carcinoma (BCC) is the most common malignant neoplasm of humans increasing theatrically all over the world. For curing BCC, Anti-Cancer Skin Lotion was made from Mentha piperita L. (Labiatae). The experiment was performed on sixteen genetically engineered mice models (GEMM) aimed at modelling human BCC and their respective precancerous lesions. By Using TNM SYSTEM, the staging and layering of basal cell carcinoma were identified. Through biopsy carcinoma effected cells were studied under electron microscope. According to RCBD different doses of treatment were applied topically on BCC affected mice and compared with a control group. Cell viability assay was used to assess the in vitro effect of mint oil after 3 weeks of treatment. Mint lotion was applied two times per day. It was observed that the mice treated with 10mg/kg showed significant result and healed upto 35% after 3 weeks. Morphology was observed under inverted phase contrast electron microscopy. Cancers require blood supply to survive and grow, Mint enzymes targeted and destroyed these blood vessels and penetrated the skin tissue and moved its way around the healthy cells to find cancer infected cells. Once these cells were located the two BEC5 actives were activated to perform their duties. The first active containing a receptor is the key to the cancer cell door. Once inside, the second active finds the stomach of the cell and destroys the stomach, killing the cancer. The study suggests that Mentha piperita has potential to prevent and cure therapeutic cancer